Foundation for Neglected Disease Research, Bangalore and Blockchain For Impact (BFI) Collaborate to Accelerate Biomedical Innovation bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.
Get latest articles and stories on Business at LatestLY. Bangalore (Karnataka) [India], November 29: Foundation for Neglected Disease Research (FNDR) is proud to announce that its partners, Bill & Melinda Gates Medical Research Institute and TB Alliance, have successfully completed the Phase 2A Early Bactericidal Activity clinical trial of TBA-7371, a novel DprE1 inhibitor for the treatment of tuberculosis. The results were presented at the 2023 Union World Conference on Lung Health in Paris. TBA-7371 was well tolerated and showed significant dose-dependent bactericidal activity with 14 days of treatment in patients with drug-susceptible pulmonary tuberculosis. TBA-7371 could have significant potential in the treatment of TB. Business News | Positive Results from Phase 2A Clinical Trial of TBA-7371, a New Drug Candidate for Tuberculosis.
Bangalore (Karnataka) [India]/ Barcelona [Spain], March 21 (ANI/PRNewswire): Foundation for Neglected Disease Research (FNDR) and DevsHealth have announced the start of a collaborative project to develop new broad-spectrum antiviral agents for infections caused by flaviviruses such as dengue, Zika, West Nile virus, and Japanese encephalitis, among others.